Fig. 2
In vivo biodistribution and TAT/CDT based on 211At-ATE-MnO2-BSA. (a-b) Biodistribution of free 211At, 211At-ATE-MnO2-BSA in 4 T1 (a) and CT26 (b) mice at 12 h post i.t. injection. Error bars represent mean ± standard deviation (s.d.) (n = 3). (c) Tumor growth curves of each mouse in different groups. (d) Time-dependent tumor volume variations of 4 T1 tumor-bearing mice experiencing corresponding treatments in different groups. Error bars represent mean ± s.d. (n = 4). (e) Body weight variations of 4 T1 tumor-bearing Balb/c mice during treatment. Error bars represent mean ± s.d. (n = 4). (f) Optical microscopic images of H&E and TUNEL-stained tumor sections in different treatment groups. (g) FACS plots and statistical data of DC maturation induced by 211At-ATE-MnO2-BSA on mice bearing CT26 tumors. Tumors were collected 3 days after treatments and assessed by flow cytometry after stain with CD11c, CD80 and CD86. Error bars represent mean ± s.d. (n = 3). Note, 1: Control, 2:MnO2-BSA, 3: free 211At, 4: 211At-ATE-MnO2-BSA. P values were calculated by t-test (*P<0.05, **P < 0.01 and ***P < 0.001)